What is the translation of " DAPTOMYCIN " in Danish?

• daptomycin

Examples of using Daptomycin in English and their translations into Danish

Each vial contains 350 mg daptomycin.
Hvert hætteglas indeholder 350 mg daptomycin.

Elimination Daptomycin is excreted primarily by the kidneys.
Elimination Daptomycin udskilles primært via nyrerne.

It contains the active substance daptomycin.
Det indeholder det aktive stof daptomycin.

It is not known whether daptomycin is excreted in human milk.
Det vides ikke om daptomycin udskilles i human modermælk.

Daptomycin is an antibiotic that can stop the growth of certain bacteria.
Daptomycin er et antibiotikum, som kan stoppe væksten af visse bakterier.

The active substance in Cubicin, daptomycin, is an antibiotic.
Det aktive stof i Cubicin, daptomycin, er et antibiotika.

Excretion of daptomycin into milk of lactating animals has not been studied.
Udskillelse af daptomycin i modermælk hos diegivende dyr er ikke undersøgt.

The active substance in Cubicin powder for concentrate for solution for infusion is daptomycin.
Det aktive stof i Cubicin pulver til koncentrat til infusionsvæske, opløsning, er daptomycin.

Daptomycin undergoes little to no Cytochrome P450(CYP450) mediated metabolism.
Daptomycin undergår kun en lille til slet ingen cytokrom P450(CYP450) medieret metabolisme.

Gender No clinically significant gender-related differences in daptomycin pharmacokinetics have been observed.
Køn Der er ikke observeret forskelle med hensyn til køn i daptomycins farmakokinetik.

Daptomycin is reversibly bound to human plasma proteins in a concentration independent manner.
Daptomycin bindes på en koncentrationsuafhængig måde, reversibelt til humane plasmaproteiner.

No dosage adjustment is necessary when administering daptomycin in patients with moderate hepatic insufficiency.
En dosisjustering er ikke nødvendig, når daptomycin administreres til patienter med moderat leverinsufficiens.

Daptomycin was not mutagenic or clastogenic in a battery of in vivo and in vitro genotoxicity tests.
Daptomycin viste ingen mutagen eller clastogen effekt i en række in vivo og in vitro genotoksicitetstests.

There is limited information on the safety and efficacy of daptomycin in the very obese and so caution is recommended.
Der er kun begrænsede data om sikkerhed og effekt af daptomycin hos meget adipøse patienter, og derfor tilrådes forsigtighed.

The decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.
At anvende daptomycin bør tage højde for organismens antibakterielle følsomhed og bør være baseret på ekspert- rådgivning.

There is limited experience regarding concomitant administration of daptomycin with other medicinal products that may trigger myopathy.
Der er kun begrænset erfaring med samtidig administration af daptomycin og andre lægemidler, som kan udløse myopati.

PK/ PD relationship Daptomycin exhibits rapid, concentration dependent bactericidal activity against sensitive Gram positive organisms in vitro.
PK/ PD forhold Daptomycin udviser in vitro hurtig, koncentrationsafhængig bakteriedræbende aktivitet mod Gram- positive organismer.

Additive activity or weak synergy with amikacin and levofloxacin has been seen for Pseudomonas aeruginosa and for gram-positive bacteria with daptomycin, linezolid, levofloxacin, and vancomycin.
Der er set additiv aktivitet over for eller svag synergi med amikacin og levofloxacin for Pseudomonas aeruginosa og for grampositive bakterier med daptomycin, linezolid, levofloxacin og vancomycin.

Therefore, caution is advised when daptomycin is co- administered with any other medicinal product known to reduce renal filtration.
Der rådes derfor til forsigtighed, når daptomycin administreres samtidig med ethvert andet lægemiddel, som er kendt for at reducere den renale filtration.

Metabolism In vitro studies have demonstrated that there is no or limited liver microsomal mediated metabolism of daptomycin in humans and that CYP450 involvement in daptomycin metabolism is minimal.
Metabolisme In vitro- forsøg har vist, at der kun er begrænset eller ingen mikrosomal- medieret levermetabolisme af daptomycin hos mennesker, og at CYP450- systemet kun er minimalt involveret i daptomycins metabolisme.

In addition, dose regimens of daptomycin that might be appropriate for the treatment of enterococcal infections, with or without bacteraemia, have not been identified.
Desuden er der ikke blevet fastlagt nogen dosisregimer for daptomycin, som vil være passende til behandlingen af enterokok- infektioner med eller uden bakteriæmi.

In obese subjects with Body Mass Index(BMI)> 40 kg/ m2 but with creatinine clearance> 70 ml/ min, the AUC0-∞ daptomycin was significantly increased(mean 42% higher) compared with non-obese matched controls.
Hos adipøse patienter med BMI(Body Mass Index)> 40 kg/ m2 men med kreatininclearance> 70 ml/ min, var daptomycins AUC0- ∞ signifikant forøget(middelværdi 42% højere) sammenlignet med ikke- adipøse matchede kontroller.

Daptomycin pharmacokinetics are generally linear and time-independent at doses of 4 to 12 mg/ kg administered as a single daily dose for up to 14 days in healthy volunteers.
Daptomycins farmakokinetik er generelt lineær og uafhængig af tid ved doser på 4 til 12 mg/ kg administreret som enkeltdosis én gang daglig i op til 14 dage i raske frivillige.

If unexplained abnormalities of PT/ INR are observed in patients taking daptomycin, consideration should be given to a possible in vitro interaction with the laboratory test.
Hvis der fremkommer uforklarlige abnormaliteter af PT/ INR hos patienter, der behandles med daptomycin, bør en mulig in vitro- interaktion med laboratorieundersøgelsen tages i betragtning.

Daptomycin is primarily cleared by renal filtration and so plasma levels may be increased during co- administration with medicinal products that reduce renal filtration e. g.
Daptomycin elimineres primært ved renal filtration, og derfor kan plasmaniveauer være forhøjede ved samtidig administration af lægemidler, som reducerer renal filtration f. eks.

In addition there are no data to support the use of 6 mg/ kg daptomycin once daily in patients with RIE or with cSSTI associated with bacteraemia whose creatinine clearance is< 50 ml/ min.
Derudover er der ingen data, der understøtter anvendelsen af 6 mg/ kg daptomycin én gang daglig til patienter med RIE eller med cSSTI associeret med bakteriæmi, hvis kreatininclearance er< 50 ml/ min.

Therefore, it is recommended that:• Plasma CPK should be measured at baseline and at regular intervals(at least once weekly) during therapy in all patients.• It cannot be ruled out that those patients with CPK greater than 5 times upper limit of normal at baseline may be at increased risk of further increases during daptomycin therapy.
Følgende anbefales derfor:• Plasma- CPK bør måles ved baseline og i regelmæssige intervaller(mindst én gang om ugen) under hele behandlingen hos alle patienter.• Det kan ikke udelukkes, at patienter, hvis CPK- værdi overstiger 5 gange den øvre grænse for normalværdi ved baseline, kan have større risiko for yderligere stigninger under behandlingen med daptomycin.

In vitro studies have determined that daptomycin does not inhibit or induce the activities of clinically significant human CYP isoforms 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, 3A4.
I in vitro- undersøgelser blev det fastslået, at daptomycin hverken hæmmer eller fremkalder klinisk signifikant aktivitet i humane CYP- isoformer lA2, 2A6, 2C9, 2C19, 2D6, 2E1, 3A4.

Renal insufficiency Following administration of a single 4 mg/ kg or 6 mg/ kg dose of daptomycin to subjects with various degrees of renal insufficiency, daptomycin clearance(CL) was reduced and systemic exposure(AUC) was increased.
Nyreinsufficiens Efter administration af en enkeltdosis på 4 mg/ kg eller 6 mg/ kg daptomycin til patienter med forskellige grader af nyreinsufficiens, var daptomycins clearance(CL) nedsat og systemisk eksposition(AUC) forhøjet.

Concomitant administration of probenecid and daptomycin has no effect on daptomycin pharmacokinetics in humans suggesting minimal to no active tubular secretion of daptomycin.
Samtidig administration af probenecid og daptomycin har ingen effekt på daptomycins farmakokinetik hos mennesker, hvilket tyder på minimal eller ingen tubulær sekretion af daptomycin.

How to use "daptomycin" in an English sentence

in vitro synergy between daptomycin and ampicillin against.

Daptomycin might be considered in such therapy-refractory cases.

In summary, AFN-1252 significantly enhances daptomycin activity against S.

aureus releases phospholipids in response to daptomycin is unknown.

AFN-1252 blocks phospholipid release and therefore preserves daptomycin activity.

Daptomycin targets bacterial cytoplasmic membrane, where it forms oligomers.

Daptomycin package insert in-use shelf life specified in PI.

A current perspective on daptomycin for the clinical microbiologist.

The MIC of daptomycin would increase after vancomycin treatment.

Daptomycin resistance did not emerge over the study period.

How to use "daptomycin" in a Danish sentence

Dette bør tages i betragtning, når behandling med daptomycin initieres, og sådanne patienter bør kontrolleres mere end én gang om ugen, hvis daptomycin administreres.

If worse clinically consider IV Vanco or Daptomycin for CA-MRSA.

Daptomycin Hospira bør kun administreres til sådanne patienter, hvis det forventes, at den mulige kliniske fordel opvejer den potentielle risiko.

Daptomycin Hospira er derfor ikke indiceret til behandling af pneumoni.

I de fleste rapporterede tilfælde associeret med daptomycin udviklede patienterne feber, dyspnø med hypoksisk respirationsinsufficiens og diffuse lungeinfiltrater.

A positive control row of Daptomycin and negative control of methanol extract of LB media only was incorporated in every replicate.

Linezolid Linezolid og daptomycin Daptomycin har gode farmakokinetiske karakteristika omkring 80% af stabil indhold i cerebrospinalvæsken af patienter efter neurokirurgi på intensivafdelinger.

Desuden er der ikke blevet fastlagt nogen doseringsregimer for daptomycin, som vil være passende til behandling af enterokok-infektioner med eller uden bakteriæmi.

Daptomycin virker på: Grampositive kokker, især Staphylococcus aureus (inkl.

Indtil videre kan daptomycin kun anbefales til: behandling af alvorlige hud- og bløddelsinfektioner S.